ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Also Senate approves spending bill.

January 23, 2004

CMF Studies Show Higher Recurrence for Post-Menopausal Patients – Caldwell

November 12, 1976

Six Compounds Carcinogenic, Risk to Humans, CH Subgroup Finds

February 2, 1979

Nine Saturation Program Planning Winners Names NCI May Reissue RFP Later This Year

May 23, 1975

Darbepoetin Didn’t Decrease Blood Transfusions, Lowered Overall Survival, Study Finds

April 27, 2007

FDA Discloses Responses, Toxicities For Burzynski’s “Antineoplastons”

April 24, 1998